{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:20:29Z","timestamp":1783689629302,"version":"3.55.0"},"reference-count":10,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2020.549931","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T05:37:43Z","timestamp":1603345063000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Refractory Auto-Immune Thrombotic Thrombocytopenic Pupura Successfully Treated With Caplacizumab"],"prefix":"10.3389","volume":"7","author":[{"given":"Chlo\u00e9","family":"Mellaza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Marie","family":"Fayolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satar","family":"Mortaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Subra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Veyradier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Coppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Augusto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17020","DOI":"10.1038\/nrdp.2017.20","article-title":"Thrombotic thrombocytopenic purpura","volume":"3","author":"Kremer Hovinga","year":"2017","journal-title":"Nat Rev Dis Primers."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.1182\/blood-2014-11-551580","article-title":"How i treat refractory thrombotic thrombocytopenic purpura","volume":"125","author":"Sayani","year":"2015","journal-title":"Blood."},{"key":"B4","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1182\/blood-2016-12-758656","article-title":"Presenting adamts13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura","volume":"130","author":"Alwan","year":"2017","journal-title":"Blood."},{"key":"B5","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMe1515876","article-title":"Von willebrand factor\u2013a new target for ttp treatment?","volume":"374","author":"Veyradier","year":"2016","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.transci.2018.03.005","article-title":"Efficacy of eculizumab in severe adamts13-deficient thrombotic thrombocytopenic purpura (ttp) refractory to standard therapies","volume":"57","author":"Vigna","year":"2018","journal-title":"Transfus Apher Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1111\/j.1537-2995.2012.03578.x","article-title":"Splenectomy and\/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA reference center experience","volume":"52","author":"Beloncle","year":"2012","journal-title":"Transfusion."},{"key":"B10","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/j.1365-2141.2005.05681.x","article-title":"Splenectomy for the treatment of thrombotic thrombocytopenic purpura","volume":"130","author":"Kappers-Klunne","year":"2005","journal-title":"Br J Haematol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2020.549931\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T05:37:44Z","timestamp":1603345064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2020.549931\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,22]]},"references-count":10,"alternative-id":["10.3389\/fmed.2020.549931"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2020.549931","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,22]]},"article-number":"549931"}}